84
Participants
Start Date
October 31, 2011
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
brentuximab vedotin
1.8 mg/kg every 3 weeks by intravenous (IV) infusion
brentuximab vedotin
2.4 mg/kg every 3 weeks by intravenous (IV) infusion
brentuximab vedotin
1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
New York Oncology Hematology, P.C., Albany
Virginia Cancer Specialists, PC, Fairfax
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg
St. Francis Hospital, Greenville
Mayo Clinic Cancer Center, Jacksonville
Ocala Oncology Center, Ocala
Indiana University Simon Cancer Center, Indianapolis
Minnesota Oncology Hematology P.A., Minneapolis
Texas Oncology - Medical City Dallas, Dallas
Texas Oncology - Dallas Presbyterian, Dallas
Texas Oncology - Bedford, Bedford
Texas Oncology - Fort Worth 12th Avenue, Fort Worth
Texas Oncology Denton South, Denton
Texas Oncology - Waco, Waco
MD Anderson Cancer Center Leukemia Group, Houston
Cancer Centers of South Texas - HOAST, San Antonio
Texas Oncology - Central Austin Cancer Center, Round Rock
Rocky Mountain Cancer Centers - Aurora, Aurora
PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists, Oxnard
Northwest Cancer Specialists, P.C., Tulatin
Willamette Valley Cancer and Research / USOR, Eugene
Puget Sound Cancer Centers, Edmonds
Yakima Valley Memorial Hospital / North Star Lodge, Yakima
Cancer Care Northwest, Spokane Valley
University of Alabama at Birmingham, Birmingham
City of Hope, Duarte
Dana-Farber Cancer Institute, Boston
University Hospitals Case Medical Center, Cleveland
MD Anderson Cancer Center / University of Texas, Houston
Seagen Inc.
INDUSTRY